Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Naporafenib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Naporafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Tovorafenib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Tovorafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Midostaurin |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Midostaurin
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Gilteritinib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Gilteritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Quizartinib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Quizartinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Crenolanib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Crenolanib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Sorafenib (AML use) |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Sorafenib (AML use)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Pexmetinib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Pexmetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Ruxolitinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Ruxolitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Fedratinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Fedratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Momelotinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Momelotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Pacritinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Pacritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
NaporafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
TovorafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
MidostaurinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
GilteritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
QuizartinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
CrenolanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
Sorafenib (AML use)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
PexmetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
RuxolitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
FedratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
MomelotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
PacritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|